185040-32-8Relevant articles and documents
Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling
Nikhar, Sameer,Siokas, Ioannis,Schlicher, Lisa,Lee, Seungheon,Gyrd-Hansen, Mads,Degterev, Alexei,Cuny, Gregory D.
, (2021/02/22)
Receptor interacting protein kinase-2 (RIPK2) is an enzyme involved in the transduction of pro-inflammatory nucleotide-binding oligomerization domain (NOD) cell signaling, a pathway implicated in numerous chronic inflammatory conditions. Herein, a pyrido[
Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma
Liu, Haibo,Niu, Deqiang,Tham Sjin, Robert Tjin,Dubrovskiy, Alex,Zhu, Zhendong,Mcdonald, Joseph J.,Fahnoe, Kelly,Wang, Zhigang,Munson, Mark,Scholte, Andrew,Barrague, Matthieu,Fitzgerald, Maria,Liu, Jinyu,Kothe, Michael,Sun, Fangxian,Murtie, Joshua,Ge, Jie,Rocnik, Jennifer,Harvey, Darren,Ospina, Beatriz,Perron, Keli,Zheng, Gang,Shehu, Elvis,D'Agostino, Laura Akullian
supporting information, p. 1899 - 1904 (2020/11/09)
Hepatocellular carcinoma (HCC) accounts for a majority of primary liver cancer and is one of the most common forms of cancer worldwide. Aberrant signaling of the FGF19-FGFR4 pathway leads to HCC in mice and is hypothesized to be a driver in FGF19 amplifie
PYRIDO[2,3-D]PYRIMIDIN-7ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
-
Paragraph 0057-0058; 0006; 0008, (2018/12/13)
Identified compounds demonstrate protein kinase inhibitory activity. More specifically, the compounds having the structures below (I) are demonstrated to inhibit receptor interacting kinase 2 (RIPK2) and/or Activin-like kinase 2 (ALK2). Compounds that are either dual RIPK2/ ALK2 inhibitors or that preferentially inhibit RIPK2 or ALK2 could provide therapeutic benefit.
